How do PD drugs influence the immune cells in the brain in pharmacology?

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein-containing Lewy bodies. While dopamine depletion is the primary pathological hallmark, neuroinflammation is now recognized as a significant factor in disease progression. Understanding how pharmacological treatments interact with the brain's immune environment is a focus of current preclinical research. As a contract research organization (CRO) specializing in non-human primate (NHP) models, Prisys Biotech provides the translational platforms required to investigate these neuro-immune interactions.

The central nervous system (CNS) immune response in PD involves resident microglia, astrocytes, and infiltrating peripheral immune cells. Microglia, the primary resident immune cells, monitor the CNS microenvironment to maintain homeostasis. In PD, pathological stimuli-such as aggregated α-synuclein-induce microglial activation.

Activated microglia can transition to a pro-inflammatory state, releasing cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). These mediators can contribute to neuronal injury. Astrocytes also participate in the immune response; they can be activated by microglial signals, potentially sustaining an inflammatory environment. Furthermore, peripheral T-cells have been observed in the SNpc of PD patients, where they may interact with neuronal antigens and further modulate the inflammatory milieu.

Levodopa

Levodopa remains the standard symptomatic treatment for PD. It crosses the blood-brain barrier and is converted into dopamine. Beyond its role in replenishing dopamine levels, levodopa has shown potential immunomodulatory properties in preclinical studies.

Evidence from certain models suggests that levodopa may influence microglial activity. In vitro research indicates that levodopa can reduce the production of pro-inflammatory cytokines, possibly through the inhibition of the nuclear factor-kappa B (NF-κB) signaling pathway. However, long-term levodopa therapy is associated with motor complications, such as levodopa-induced dyskinesia (LID). Research into whether chronic administration alters immune cell profiles or contributes to sustained inflammation is ongoing.

Dopamine Agonists

Dopamine agonists, such as pramipexole and ropinirole, directly activate dopamine receptors. These agents are utilized in early-stage PD or as adjuncts to levodopa.

Pramipexole has demonstrated anti-inflammatory effects in various animal models, characterized by reduced microglial activation and decreased cytokine release. These effects may be mediated via dopamine D2 and D3 receptors expressed on glial cells. Similarly, ropinirole may reduce the activation of both microglia and astrocytes, potentially offering a degree of modulation against inflammation-mediated neuronal damage.

MAO-B Inhibitors

Monoamine oxidase-B (MAO-B) inhibitors, including selegiline and rasagiline, extend dopamine activity by inhibiting its degradation. These compounds also exhibit properties that affect the immune response.

Selegiline has been reported to reduce microglial activation and the production of reactive oxygen species (ROS). Rasagiline has shown similar effects, with studies indicating an ability to inhibit NF-κB activation in microglia. By reducing the output of pro-inflammatory mediators, MAO-B inhibitors may influence the rate of neurodegeneration associated with chronic inflammation.

Characterizing the effects of PD drugs on the immune system is necessary for several reasons:

• Therapeutic Optimization: Identifying agents that modulate neuroinflammation may allow for the development of strategies that address both symptoms and disease progression.
• Side Effect Management: Understanding the relationship between long-term drug use and immune cell changes can assist in mitigating complications such as dyskinesia.
• Pathophysiological Insights: Studying the interaction between dopaminergic agents and immune cells provides data on the underlying mechanisms of PD, supporting the identification of new therapeutic targets.

The complex immune system and brain structure of non-human primates make them the most relevant species for studying neuro-immune interactions in PD. Prisys Biotech provides established NHP models-including MPTP-induced and MPP+ targeted infusion models and AAV-α-Synuclein Overexpression NHP Model-to support these pharmacological investigations.

Prisys integrates advanced technologies to quantify the effects of PD treatments:

• Precision Dosing: MRI-Guided Drug Delivery (RT-iMRI) and convection-enhanced delivery (CED) enable the targeted administration of therapeutics directly into functional brain regions, such as the striatum or substantia nigra.
• Imaging Capabilities: PET/CT and fMRI are used to monitor dopamine transporter (DAT) levels, metabolic changes, and neuroinflammation in life.
• Automated Behavioral Analysis: The BehaviorAtlas® system utilizes AI-based NHP Behavior Analysis System to provide objective, quantitative data on motor function and drug efficacy.

Prisys Biotech also offers models for conditions that may share inflammatory pathways with PD. For instance, metabolic dysfunction-studied in Hyperlipidemia and NASH models-is increasingly linked to systemic and central inflammation. Additionally, Idiopathic Pulmonary Fibrosis (IPF) models allow for the study of fibrotic and inflammatory mechanisms that may parallel certain processes in neurodegenerative disorders.

Prisys Biotech provides comprehensive preclinical services, from study design to necropsy and histopathological analysis. Our technical team offers expertise in NHP pharmacology and neurology to assist researchers in evaluating the neuro-immune effects of novel candidates. Contact Prisys Biotech to discuss NHP model availability and translational research support.

Contact Prisys Biotech

References

Hirsch, E. C., & Hunot, S. (2009). Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology, 8(4), 382-397.

McGeer, P. L., & McGeer, E. G. (2008). Inflammation and Parkinson's disease. Movement Disorders, 23(Suppl 3), S239-S246.

Tansey, M. G., & Goldberg, M. S. (2010). Inflammation in Parkinson's disease: a target for neuroprotection? Nature Reviews Neurology, 6(1), 30-40.

Teismann, P., & Schulz, J. B. (2004). Oxidative stress and mitochondrial dysfunction in Parkinson disease. Journal of Neural Transmission, 111(8), 1031-1050.